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An anti-poxvirus vaccine based on replicon particles of Venezuelan equine encephalitis virus (VRP) is being developed. The cowpox virus genes
encoding structural proteins corresponding to vaccinia virus proteins A33, B5, andA27were each expressed fromVRP. High serum IgG titers against
these proteins were generated in BALB/c mice vaccinated with each of these VRP. VRP induced both IgG1 and IgG2a with a strong predominance of
IgG2a production. The response is long-lasting, as evidenced by the retention of high anti-B5 serum IgG titers through at least 50 weeks after priming
immunization. Mice vaccinated with B5-, A33- or A27-VRP individually or together survived intranasal challenge with cowpox virus, with the
multivalent vaccine formulation providing more effective protection from weight loss and clinical signs of illness than the monovalent vaccines.
These results demonstrate that VRP may provide an effective alternative to vaccinia virus vaccines against poxvirus infection.
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The Poxviridae are a family of enveloped viruses with large,
linear double stranded DNA genomes ranging in size from 130 to
300 kilobase pairs (kbp) that replicate in the cytoplasm of infected
cells. The family is divided into two subgroups: Chordopoxviri-
nae and Entomopoxvirinae. Chordopoxvirinae have a vertebrate
host range and are divided into eight genera, one of which
contains the Orthopoxviruses, including camelpox, cowpox,
ectromelia (mousepox), monkeypox, raccoonpox, skunkpox,
vaccinia and variola virus, the etiologic agent of smallpox. The
orthopoxviruses each have a genome of about 200 kbp typically
encoding more than 150 proteins. During the viral life cycle,
maturation of the virus results in two major infectious forms of
virus: intracellular mature virus particles (MV) and extracellular⁎ Corresponding author.
E-mail address: nthornbu@med.unc.edu (N.J. Thornburg).
0042-6822/$ - see front matter © 2007 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2007.01.001enveloped virus particles (EV), which have different repertoires of
viral envelope proteins (Moss, 2001; Moss, 2006).
Throughout history, smallpox has been one of the most
feared human diseases. In 1977, variola virus was eradicated
from the natural environment after a World Health Organization
vaccination campaign employing live vaccinia virus vaccines.
Although these vaccines were effective against variola virus,
they were associated with a high frequency of complications
ranging in severity from mild to life-threatening (Fulginiti et al.,
2003). Consequently, as smallpox was eradicated around the
world, routine vaccination against this disease was discon-
tinued. In the ensuing absence of any natural threat of smallpox,
a large proportion of the world's population has never received
vaccination against smallpox or acquired natural resistance to
the disease. Individuals vaccinated before the 1980s may also
lack protection against orthopoxvirus infection because vacci-
nees may lose neutralizing antibodies in the third decade after
vaccination (Viner and Isaacs, 2005). Cessation of vaccination
and waning immunity has left a large and growing proportion of
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of natural wild type or weaponized orthopoxviruses (Henderson,
1999). Furthermore, orthopoxviruses are significant zoonotic
pathogens (Hutin et al., 2001; Nalca et al., 2005; Stephenson,
2003). Epidemics of human monkeypox occur sporadically
throughout central and west Africa, and an outbreak of
monkeypox was reported in the US Midwest in 2003 after
infected pet prairie dogs exposed humans to monkeypox virus
(Hutin et al., 2001; Nalca et al., 2005; Stephenson, 2003).
The threat of bioterrorist attacks and natural zoonotic
orthopoxviral outbreaks has prompted a resumption of
vaccination programs to protect certain groups. However, the
risks of serious side effects from current vaccinia virus vaccines
remain and the resulting low vaccination rates provide the
impetus for renewed efforts to develop safe and effective
alternatives to live vaccinia virus vaccines.
One strategy to reduce virus-associated complications is to
vaccinate not with whole live virus, but with components of
the virus known to induce protective immunity. Several MV
envelope proteins have been identified as targets of neutrali-
zing antibodies, including A27, L1, H3 and D8 proteins
(Davies et al., 2005; Hsiao et al., 1999; Ichihashi and Oie,
1996; Lin et al., 2000; Rodriguez et al., 1985; Wolffe et al.,
1995). Furthermore, antibodies against B5 protein neutralize
EVs (Bell et al., 2004). Several studies have suggested that
these targets can be used as subunit vaccines in the form of
DNA or purified proteins. His-tagged vaccinia virus A33 and
B5 proteins purified from bacteria protected mice against
vaccinia virus challenge (Galmiche et al., 1999). B5, L1, A33
and A27 DNA vaccines protected mice from vaccinia virus
challenge and non-human primates from lethal monkeypox
virus challenge (Hooper et al., 2000, 2003, 2004; Pulford et al.,
2004). Protection was most effective using a combination of
MV and EV antigens (Hooper et al., 2003). Vaccination with
purified L1, A33 and B5 proteins also protected mice from
vaccinia challenge better than mice immunized with live
vaccinia virus (Fogg et al., 2004), and purified A33 protects
mice from ectromelia (mousepox) challenge (Fang et al.,
2006). Protection with purified proteins is antibody mediated
as passive transfer of monoclonal and polyclonal antibodies
also protects mice from lethal vaccinia virus challenge when
administered either prophylactically or therapeutically (Lustig
et al., 2004).
An alternative vaccine system to deliver subunits of the virus
employs single-cycle replicons of Venezuelan equine encepha-
litis virus (VEE). VEE is an alphavirus within the family To-
gaviridae with a positive sense 11.5-kbp RNA genome that
replicates in the cytoplasm of infected cells (Schlesinger, 2001).
The 5′ two-thirds region of the genome encodes non-structural
replicase/transcriptase proteins, and the 3′ third region encodes
capsid and E1/E2 glycoproteins downstream of a strong,
internal 26S subgenomic mRNA promoter.
VEE replicon particles (VRP) are produced by replacing the
structural genes in the VEE genome with heterologous
immunogen. The modified VEE genome is co-electroporated
into packaging cells with the structural genes provided in trans
from two helper RNAs, and VRP containing replicon genomesinfect cells and express the transgene, but cannot produce
progeny virions (Pushko et al., 1997). In cells infected with
VRP in vivo high levels of antigen are produced and both
systemic and mucosal immunity are induced in a broad range of
species (Davis et al., 2002; Dong et al., 2003; Johnston et al.,
2005; Pushko et al., 1997; Schultz-Cherry et al., 2000). VRP
directly infect dendritic cells (MacDonald and Johnston, 2000;
Moran et al., 2005) and provide adjuvant activity independent
of transgene expression (Thompson et al., 2006). VRP
expressing gag from HIV clade C have completed Phase I
clinical trials in the United States and Africa. Preliminary data
analysis indicates that VRP appear to be safe and to elicit
antibodies (Callay I, personal communication).
In this study, we have used a cowpox virus/mouse model of
infection to determine if the VEE–VRP system will also pro-
vide an effective subunit vaccine protective against orthopox-
virus infection.
Results
Expression of cowpox virus genes from VRP
Several vaccinia virus proteins have been identified as
targets of neutralizing antibodies. These include the MV surface
proteins A27 (Rodriguez et al., 1985), L1 (Wolffe et al., 1995),
H3 (Lin et al., 2000) and D8 (Hsiao et al., 1999), as well as the
EV surface protein B5 (Aldaz-Carroll et al., 2005; Bell et al.,
2004; Galmiche et al., 1999; Law and Smith, 2001).
Furthermore, antibodies against A33 are protective in vivo
even though they do not elicit neutralizing antibodies (Galmiche
et al., 1999). Specifically, vaccinating with a combination of
MV and EV antigens protects animals against vaccinia and
monkeypox challenge (Fogg et al., 2004; Hooper et al., 2003;
Hooper et al., 2004).
VRP were engineered to express three proteins encoded by
the Brighton red strain of cowpox virus (CPXV): two EV
antigens, CPXV199 and CPXV168 proteins (similar to vaccinia
virus Copenhagen B5 and A33), and one MV antigen,
CPXV162 protein (similar to vaccinia virus Copenhagen
A27) (Goebel et al., 1990; Massung et al., 1994). In comparing
amino acid sequences, CPXV199 protein has 93% identity/
97% similarity to vaccinia virus Copenhagen B5 protein, and
94% identity/97% similarity to the corresponding protein
encoded by variola virus Bangladesh 1975, while vaccinia
virus Copenhagen B5 protein also shares 93% identity/97%
similarity with this variola virus major protein (Fig. 1). The
CPXV168 protein shares 96% identity/97% similarity to
vaccinia virus Copenhagen A33, and 90% identity/94%
similarity to the corresponding protein of variola virus, while
the vaccinia virus A33 protein shares 94% identity/96%
similarity to the corresponding protein encoded by variola
virus (Fig. 1). The CPXV163 protein shares 97% identity/98%
similarity to vaccinia virus Copenhagen A27 protein, and 98%
identity/100% similarity to the corresponding variola virus MV
surface protein. The vaccinia virus Copenhagen A27 protein
also shares 97% identity/98% similarity to the corresponding
variola virus protein (Fig. 1).
Fig. 2. Expression of cowpox virus genes from VRP infection. CPXV199
(similar to vaccinia virus B5), CPXV168 (similar to vaccinia virus A33) and
CPXV162 (similar to vaccinia virus A27) genes from the cowpox virus
(Brighton red) were cloned into VEE replicon vectors and packaged in VRP.
BHK cells were infected with VRP and infected cell lysates were used for
immunoblot with a polyclonal vaccinia virus antibody.
Fig. 1. Amino acid comparison of variola, cowpox and vaccinia virus antigens. Three genes from cowpox virus Brighton red were cloned into VEE replicon vectors. An
amino acid alignment was performed to compare cowpox virus sequences to variola virus Bangladesh 1975 and vaccinia virus Copenhagen sequences. Underlined amino
acids indicate a difference in amino acid in comparison to the variola virus sequence. Deletions are indicated with *. The top panel compares variola virus B6 (Bangladesh
1975) with CPXV199 and vaccinia virus Copenhagen B5 proteins. The middle panel compares variola virus A36 (Bangladesh 1975) with CPXV168 and vaccinia virus
Copenhagen A33 proteins. The bottom panel compares variola virus A31 (Bangladesh 1975) with CPXV162 and vaccinia virus Copenhagen A27 proteins.
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kidney (BHK) cells were infected with VRP at multiplicities of
infection (MOI) of 3. Cells were harvested at 12 h post-
infection, and the expression of cowpox virus antigens was
confirmed by immunoblot with a polyclonal anti-vaccinia virus
antibody cross-reactive with cowpox virus proteins. The
predicted molecular weights of B5, A33, and A27 are
35 kDa, 20.5 kDa, and 12.6 kDa respectively, and antigens
corresponding to the predicted molecular weights were
expressed in VRP infected cells (Fig. 2).
B5-VRP induces long-lasting, high levels of anti-B5 serum IgG
While T-cell responses contribute to poxvirus immunity, an
antibody response is necessary and sufficient to protect
macaques against a lethal monkeypox challenge and mice
against secondary infection with ectromelia virus (Edghill-Smith
et al., 2005; Panchanathan et al., 2006). B5 is an EV envelope
protein that contributes to protection against vaccinia virus and
monkeypox (Fogg et al., 2004; Hooper et al., 2003; Hooper et al.,
2004). Furthermore, antibodies against B5 neutralize EVand are
the major neutralizing components of human vaccinia immu-
noglobulin (Bell et al., 2004; Galmiche et al., 1999).
As antibody responses appear to be the major correlate of
protection against orthopoxviral disease, the antibody response
against a VRP-based vaccine was tested. BALB/c mice wereprimed with 1×106 IU B5-VRP in the rear footpads. Mice were
boosted with the same dose of B5-VRP at 4 and 42 weeks post-
prime. Blood was collected periodically and serum IgG was
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purified B5 from vaccinia virus WR. Endpoint titers for B5-
VRP vaccinated mice were approximately 104 3 weeks post-
boost and lost approximately half a log over 38 weeks (Fig. 3A).
After the second boost, serum IgG titers rebounded. These data
indicate that B5 is immunogenic in mice, and when expressed
using the VRP system, results in lasting serum antibody titers.
In order to compare antibody responses from B5-VRP to
purified protein, BALB/c mice were primed and boosted one
time, 4 weeks post-prime with 1×106 IU B5-VRP in the rear
footpads, 10 μg purified B5 protein or PBS control. Blood
was collected 3 weeks post-boost, and anti-B5 serum IgG was
assayed by ELISA. His-tagged B5 protein was used both to
immunize mice and coat ELISA plates. To control for the
possibility that some of the observed reactivity towards the
His-tagged B5 protein was directed to the His-tag itself,
ELISA plates were coated with His-peptide, and no back-
ground was observed (data not shown). Mice vaccinated with
B5-VRP had B5 titers of approximately 1×104, 10-fold higherFig. 3. B5-VRP induces long-lasting, high levels of anti-B5 serum IgG. (A) Six-we
the rear foot-pad at time 0. Mice were boosted with the same dose at 4 and 42 wee
prime and were used for B5 ELISA. Serum IgG ELISA titers are reported as the g
greater than 0.2 at 450 nm. (B) Six-week-old BALB/c mice were primed with 1×106
weeks post-prime, mice were boosted with the same dose of VRP, protein or PBS. Ser
ELISA.than mice vaccinated with purified B5, confirming that B5
expressed from VRP infection is highly immunogenic in
BALB/c mice (Fig. 3B).
B5-VRP, A33-VRP, and A27-VRP and a cocktail of these VRP
elicit antibody responses in BALB/c mice
In order to examine the effectiveness of VRP vaccines, mice
were primed with 1×106 B5-VRP, A27-VRP, or A33-VRP
individually or as a cocktail of all three plus a fourth non-
expressing VRP for a total dose of 4×106 IU. VRP expressing
the influenza virus hemagglutinin, HA-VRP, were used as an
irrelevant vaccine control. Mice were boosted once, 4 weeks
post-prime, with the same dose of VRP.
Sera were collected 2 weeks post-boost and antibodies
against B5, A27, and A33 were detected qualitatively when sera
from individual mice were used for immunoblot against cell
lysates that were infected with cowpox virus. Whole cell lysates
from mock infected and cowpox virus Brighton red infectedek-old BALB/c mice were primed with 1×106 IU B5-VRP subcutaneously in
ks post-prime. Sera were collected at various time points up to 50 weeks post-
eometric mean of the reciprocal dilution at which the sample absorbance was
IU B5-VRP, 10 μg purified B5 or PBS subcutaneously in the rear foot-pads. Four
a were collected 2 weeks post-boost and were assayed for B5 serum IgG titers by
445N.J. Thornburg et al. / Virology 362 (2007) 441–452cells were resolved by SDS–PAGE. Sera from individual mice
were used as primary antibody. Sera from mice that were bled
prior to vaccination (Pre-Bleed) did not reveal any cross-
reactivity in uninfected or infected cell lysates (Fig. 4A, lanes 1
and 2). Sera collected 2 weeks post-boost from mice vaccinated
with HA-VRP also revealed no cross-reactivity in either
uninfected or infected cell lysates (Fig. 4D, lanes 3 and 4).
Sera from mice vaccinated with B5-VRP and A33-VRP alone
recognize appropriately sized proteins in infected cell lysates
(Fig. 4A, lanes 6 and 10). Sera from mice vaccinated with A27-
VRP alone also recognized an appropriately sized protein in
infected cell lysates (Fig. 4A, lane 12). Furthermore, anti-B5,
A33 and A27 antibodies were detected in mice vaccinated with
the 3X cocktail (Fig. 4A, lane 12).
Antibody titers were examined by B5, A33, and A27 IgG
ELISA. A33 ELISAs were performed with purified His-tagged
A33 from vaccinia virus WR, and A27 ELISAs were performed
with His-tagged A27 from cowpox virus Brighton red. Serum
anti-B5 IgG titers of mice vaccinated with B5-VRP were
approximately 104 post-boost and were not statistically differentFig. 4. B5-VRP, A33-VRP, and A27-VRP elicit an antibody responses in BALB/c mi
and A27-VRP, individually, or a cocktail of all three VRP plus a fourth non-expressin
dose 4 weeks post-prime. Sera were collected 2 weeks post-boost and used for imm
vaccinated with B5-VRP, A33-VRP and A27-VRP, individually, the 3× cocktail and
primary antibodies against uninfected 143B cell lysates and cowpox virus Brighton re
were used as a control to detect any non-specific reactivity. (B) Sera from mice vaccin
Sera from mice vaccinated with A33-VRP and the 3× cocktail were used for A33 seru
serum IgG ELISA.in mice vaccinated with the cocktail of B5, A33 and A27-VRP
(p=0.49) suggesting that immunodominance is not evident
when using multiple antigens in the VRP vaccine system (Fig.
4B). Similarly, mice vaccinated with A33-VRP alone or as a
constituent of the 3X cocktail had A33 ELISA titers of 7×103
and 4×103, respectively (Fig. 4C). Mice vaccinated with A27-
VRP alone or as a constituent of the 3X cocktail had A27
ELISA titers of 8×103 and 5×103, respectively (Fig. 4D).
MV neutralizing antibodies were assayed by plaque reduc-
tion neutralization assay. Sera from mice vaccinated with the 3X
cocktail VRP reduced plaque formation by 50% at a dilution of
approximately 1:500.
B5, A33 and A27-VRP elicit an IgG2a polarized antibody
response
Immunoglobulin G subtypes differ in their effector functions
and can be indicative of the T helper (Th) response. Th type 2
(Th2) cytokines such as IL-4 induce an isotype switch to IgG1,
and Th type 1 (Th1) cytokines, such as IFNγ, induce an isotypece. Six-week-old BALB/c mice were primed with 1×106 IU B5-VRP, A33-VRP
g VRP for a total dose of 4×106 IU (3× Cocktail). Mice were boosted at the same
unoblot and ELISA. (A) The presence of anti-cowpox virus antibody in mice
HA-VRP were detected by immunoblot. Sera from individual mice were used as
d infected 143B cell lysates. Sera from mice bled prior to vaccination (Pre-Bleed)
ated with B5-VRP and the 3× cocktail were used for B5 serum IgG ELISA. (C)
m IgG ELISA. (D) Sera from mice vaccinated with A27-VRP were used for A27
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the immunoglobulin G subtypes induced by VRP vaccination,
sera from mice vaccinated with B5-VRP, A33-VRP or A27-
VRP were characterized by means of IgG1 and IgG2a specific
ELISAs. Serum anti-B5 IgG1 titers were approximately
9.0×103 post-boost, and serum anti-B5 IgG2a titers were
3.6×104 (Fig. 5A). Serum anti-A33 IgG1 titers were 2.6×103
post-boost, and serum anti-A33 IgG2a titers were 3.8×104 (Fig.
5B). Serum anti-A27 IgG1 titers were 500 post-boost, and
serum anti-A27 IgG2a titers were 2.3×104 (Fig. 5C). TheseFig. 5. B5, A33 and A27-VRP elicit an IgG2a polarized antibody response. Six-
week-old BALB/c mice were primed with 1×106 IU B5-VRP or A33-VRP.
Mice were boosted at the same dose 4 weeks post-prime. Sera were collected
2 weeks post-boost and used for IgG subtype ELISAs. (A) Sera from mice
vaccinated with B5-VRP B5 serum IgG1 and IgG2a ELISA. (B) Sera from mice
vaccinated with A33-VRP were used for A33 serum IgG1 and IgG2a ELISA.
(C) Sera from mice vaccinated with A27-VRP were used for A27 serum IgG1
and IgG2a ELISA.data indicate that anti-B5 IgG2a:IgG1 ratio was 4:1, the anti-
A33 IgG2a:IgG1 ratio was 14:1 and the anti-A27 IgG2a:IgG1
ration was 40:1 in mice vaccinated with VRP.
Intranasal challenge of adult BALB/c mice with cowpox virus
Brighton red
Six- to 8-week-old BALB/c mice begin to show clinical
signs of illness 3–6 days after intranasal challenge with
cowpox virus, and the mice typically succumb to lethal doses
of virus 4 to 10 days after infection (Thompson et al., 1993).
Infection induces peribronchial and peribronchiolar hemor-
rhage, bronchial and bronchiolar epithelial cell hyperplasia,
and alveolar hemorrhage and edema (Thompson et al., 1993).
However, mice older than 6 to 8 weeks are more resistant to
infection than younger mice, necessitating the establishment of a
model involving the intranasal challenge of 14 to 16-week-old
BALB/c mice with cowpox virus to allow time for a standard
prime-boost regimen.
In this model system, virus infected mice began to lose
weight at approximately 5 days post-challenge with peak weight
loss at 10 days post-challenge (Fig. 6A). All mice that lost more
than 20% of their body weight were euthanized according to the
established animal protocol, though surviving mice started to
regain weight at 12 days post-challenge. The degree of weight
loss was dose dependent and animals challenged with doses
greater than 1×103 pfu lost a statistically significant amount of
weight in comparison to mock-challenged animals. Infected
mice exhibited ruffling of the fur, conjunctivitis in the eye
proximal to the challenged nostril, decreased activity and
labored breathing (Fig. 6B). Similarly, clinical signs of illness
were apparent by approximately 5 days post-challenge and were
dose dependent. Five of eight mice challenged with 1×106 pfu
cowpox virus and 5 of 8 mice challenged with 1×105 pfu
cowpox virus survived challenge. All of the mice challenged
with 1×104 pfu or 1×103 pfu cowpox virus survived. Multiple
repetitions of intranasal challenge with cowpox virus Brighton
red have indicated that this model is both predictable and
reproducible, providing an excellent screening mechanism for
candidate vaccines.
Mice vaccinated with VRP are protected from intranasal
challenge with cowpox virus Brighton red
In order to assay the protective capacity of the individual
VRP vaccines or the 3X cocktail, BALB/c mice were primed
and boosted once 4 weeks post-prime with 1×106 IU B5-VRP,
A27-VRP or A33-VRP individually or as a cocktail of all
three. HA-VRP were used as an irrelevant vaccine control.
Three weeks post-boost, mice were anesthetized and chal-
lenged intranasally with 1×106 pfu cowpox virus Brighton red.
Age-matched, unvaccinated BALB/c mice were anesthetized
and challenged, in parallel, with an equal volume of diluent to
serve as a mock-challenged control group. Mice were moni-
tored daily for weight loss and clinical signs of illness. Mock-
challenged mice did not lose any weight over the course of
the 18-day experiment or show any signs of clinical illness
Fig. 7. Mice vaccinated with VRP are protected from intranasal challenge with
cowpox virus (Brighton red). Six-week-old BALB/c mice were primed with
1×106 IU B5-VRP, A33-VRP and A27-VRP or a cocktail of all three VRP (3×
Cocktail). Mice were also primed and boosted with 1×106 IU HA-VRP as an
irrelevant vaccine control. Three weeks post-boost, mice were anesthetized with
Ketamine/xylazine and challenged with 1×106 pfu cowpox virus Brighton red.
A group of unvaccinated mice was also challenged with 5 μL diluent to serve as
mock challenge controls. (A) Mice were monitored daily for weight loss.
Statistics shown are in comparison to HA-VRP vaccinated mice challenged with
1×106 pfu cowpox virus Brighton red. (B) Challenged mice were monitored
daily for clinical signs of illness. Values are defined in Fig. 5. The number of
surviving mice per group of 8 is noted with *.
Fig. 6. Intranasal challenge of adult BALB/c mice with cowpox virus (Brighton
red). (A) Female BALB/c mice 14–16 weeks old were anesthetized with
Ketamine/xylazine intraperitoneal. Eight mice per group were challenged with
indicated doses of cowpox virus introduced into one nostril in a total volume of
5 μL. Mock-challenged mice were anesthetized and given diluent intranasally.
Mice were monitored daily for weight loss. Mice that lost more than 20% body
weight were euthanized. Statistics shown are in comparison to mock-challenged
mice. (B) Challenged mice were also monitored daily for clinical signs of illness.
0 indicates no clinical signs of illness; 1 indicates slight ruffling of fur; 2
indicates moderate signs of illness including ruffled fur, decreased activity and
conjunctivitis, 3 indicates severe signs of illness including ruffled fur, lethargy,
labored breathing, hunched posture and noticeable weight loss, and 4 indicates
non-responsive or moribund. The number of surviving mice per group of 8 is
noted with *.
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irrelevant HA-VRP exhibited significant weight loss as well as
clinical signs of illness (Figs. 7A and B). Five of eight mice
vaccinated with HA-VRP were euthanized due to weight loss in
excess of 20% and severe signs of illness (Fig. 7B). In contrast,
mice vaccinated with A33-VRP, A27-VRP, and B5-VRP alone
lost significantly less weight than HA-VRP vaccinated mice
(Fig. 7A). Only one mouse of eight vaccinated with B5-VRP
required euthanasia and none vaccinated with A33-VRP or
A27-VRP required euthanasia (Fig. 7B). Mice vaccinated with
the 3X cocktail lost very little weight and showed only mild
signs of illness (Figs. 7A and B). None of the mice vaccinated
with the 3X cocktail required euthanasia. These data indicate
that B5-VRP, A33-VRP and A27-VRP individually protect
mice against mortality and severe morbidity after cowpox virus
challenge and that these VRP vaccines work most effectively in
combination.Discussion
In this report, cowpox virus structural antigens have been
expressed from VEE replicon particles. VRP efficiently
expressed poxvirus antigens in cell culture, elicited long-lasting
serum IgG titers in mice and protected mice from intranasal
cowpox virus challenge, validating the concept of VRP-based
poxvirus vaccines.
As a result of cessation of routine vaccination against
smallpox, a majority of the world's population may now be
susceptible to fatal orthopoxvirus outbreaks, either through
naturally occurring exposures or through bioterrorist attacks.
Common side effects from vaccination with the current
vaccine include fever, malaise and enlarged lymph nodes
448 N.J. Thornburg et al. / Virology 362 (2007) 441–452(Bray and Wright, 2003). Other more serious complications
include generalized vaccinia, eczema vaccinatum, postvaccinal
encephalopathy and progressive vaccinia, which can be severe
or fatal (Bray and Wright, 2003). Furthermore, vaccination of
healthcare workers in 2003 has suggested a possible link
between vaccinia vaccination and cardiac events (Casey et al.,
2005).
Current vaccines may not be effective against genetically
engineered poxviruses. Mice that are genetically resistant to
ectromelia virus are susceptible to ectromelia virus expressing
murine IL-4 (Jackson et al., 2001). Mice previously immunized
with vaccinia virus were also susceptible to the IL-4 expressing
ectromelia virus, indicating that the engineered poxvirus
overcame otherwise protective pre-existing immunity.
The danger of vaccinia vaccination combined with the
potential that new poxviruses may be engineered to bypass
existing poxvirus immunity emphasizes the need to develop
multiple new approaches to vaccinate against poxvirus
disease. Ideally, new vaccine technologies would be safer
than vaccinia and could be developed quickly should an
engineered poxvirus emerge. Several second generation
poxvirus vaccines are currently being developed including
tissue culture produced vaccinia, modified vaccinia Ankara,
purified proteins and DNA-based vaccines (Earl et al., 2004;
Fogg et al., 2004; Hooper et al., 2000, 2003; Phelps et al.,
2005).
Studies using purified B5, A33, and L1 in combination with
Ribi or saponin adjuvants protected mice from vaccinia virus
challenge better than live vaccinia virus vaccination (Fogg et al.,
2004). B5-VRP elicited even higher serum IgG titers than
purified B5 without adjuvant, suggesting that poxvirus antigen-
expressing VRP may be more immunogenic than purified
protein alone (Fig. 4B). Furthermore, the 3X VRP cocktail
protected mice after just one prime and one boost (Figs. 7A and
B), as opposed to the 3–4 shots needed for protection with
purified proteins (Fogg et al., 2004). Currently, there is only one
FDA approved adjuvant, alum, which works well as a systemic
adjuvant, but not well as a mucosal adjuvant. VRP vaccination
is efficient without the addition of adjuvants. VRP display
adjuvant activity independent of antigen expression, bypassing
the need to use additional adjuvants (Thompson et al., 2006).
Systemic adjuvant activity provided by VRP is at least
equivalent to cholera toxin and CpG DNA, and mucosal
adjuvant activity surpasses that of cholera toxin and CpG DNA
(Thompson et al., 2006).
Vaccination with purified poxvirus proteins induces a strong
IgG1, Th2 response (Fogg et al., 2004). In contrast, vaccination
of mice with live vaccinia virus yields a IgG2a dominant
response (Fogg et al., 2004). Vaccination with B5-VRP and
A33-VRP yielded IgG2a:IgG1 ratios that were remarkably
similar to those in mice vaccinated with live vaccinia virus.
Vaccination with live vaccinia virus elicits anti-B5 IgG2a:IgG1
ratios of approximately 5:1 and anti-A33 IgG2a:IgG1 ratios of
approximately 13:1 (Fig. 5), which were very similar to the
ratios in VRP vaccinated mice (Fogg et al., 2004). Th1
cytokines, such as IFNγ, induce an isotype switch to IgG2a,
indicating that both VRP and vaccinia vaccination induce astrong Th1 response (Finkelman et al., 1990). Notably, vaccine
naive patients who received the Aventis Pasteur smallpox
vaccine also exhibited a strong Th1 cytokine response with
extremely elevated levels of IFNγ 1 week post-immunization
(Rock et al., 2004). IgG1 and IgG2a have different activities
potentially through their affinities for activating versus inhibi-
tory Fc receptors (Nimmerjahn and Ravetch, 2005). IgG2a has
also been shown to be the IgG subclass that strongly correlates
with protection against viral infections includingHerpes simplex
virus, yellow fever virus and lactate dehydrogenase-elevating
virus (Ishizaka et al., 1995; Markine-Goriaynoff and Coutelier,
2002; Schlesinger et al., 1993).
DNA vaccines encoding B5, A33, A27 and L1 have also
protected animals from poxviral diseases (Hooper et al., 2000,
2003, 2004; Pulford et al., 2004). Although DNA vaccines at
doses up to 5 mg do not elicit robust antibody responses,
antibody responses can be improved through particle-mediated
epidermal delivery or inclusion of adjuvants (Dean et al., 2005).
VRP potentially elicit strong antibody responses without the use
of specialized delivery devices or adjuvants. Furthermore, VRP
are especially attractive as potential vaccine vectors because
they can directly infect human dendritic cells, process antigens
and present antigens within the draining lymph nodes.
Specifically, human dendritic cells can be infected ex vivo,
which leads to DC maturation and cytokine secretion (Moran et
al., 2005).
Despite the ability of the 3X VRP cocktail to protect mice
from significant weight loss and illness (Figs. 7A and B),
mice vaccinated with the 3X VRP cocktail still lost
statistically significant weight in comparison to the mock-
challenged mice. These data suggest that the VRP poxvirus
vaccine still needs improvement, possibly through the
inclusion of additional antigens. Several other structural
antigens have been identified as either targets of neutralizing
antibodies and as protective immunogens (Davies et al., 2005;
Fogg et al., 2004; Hooper et al., 2000, 2003, 2004; Hsiao et
al., 1999). Mice have been successfully vaccinated with
cocktails of up to 9 different VRP without any apparent
adverse effects or lost reactivity to individually expressed
poxvirus antigens, demonstrating the ability to include
multiple antigens within a potential poxvirus vaccine product
(Thornburg and Johnston, unpublished data). Furthermore,
individual VRP can be engineered to express several antigens,
thereby facilitating manufacturing. These data suggest that
VRP poxvirus vaccines may provide a safe, viable alternative
to live vaccinia virus.
Materials and methods
Construction of VRP encoding cowpox virus structural
proteins
Coding regions of the CPXV162, CPXV168, and CPXV199
open reading frames corresponding to vaccinia virus genes A27,
A33, and B5 were amplified by PCR and inserted into a VEE
replicon plasmid pVR21 (Balasuriya et al., 2000; Pushko et al.,
1997). Cowpox virus DNAwas amplified by overlap PCR with
449N.J. Thornburg et al. / Virology 362 (2007) 441–452BD Advantage HF 2 PCR reagents (Clontech, Becton
Dickinson). In each case, the upstream PCR fragment contain-
ing the 26S VEE structural gene promoter was generated from
primers VR21F and VR21R#2 (Table 1). The coding region of
CPXV162 (A27) was generated with primers VR21F162 and
R162 (Table 1); the coding region of CPXV168 (A33) was
generated with primers F168 and 168R (Table 1); and the
coding region of CPXV199 (B5) was generated with primers
VR21F199 and R199VR21. Overlap PCR products were cloned
into pVR21 from ApaI to either AscI (CPXV199) or ClaI
(CPXV162 and CPXV168). The sequence of each construct
was confirmed by DNA sequence analyses.
Cells and viruses
BHK cells were used for VRP production and infections.
BHK cells were maintained in MEM alpha (Gibco) supple-
mented with 10% FBS or DCS, L-glutamine and tryptose-
phosphate. VRP production has been described previously
(Davis et al., 2000). Briefly, pVR21 encoding the VEE
nonstructural proteins, an encapsidation signal, and the
transgene downstream of a 26S promoter, and two helper
plasmids encoding VEE capsid and VEE E1/E2 glycoproteins
were linearized and transcribed using the mMessage in vitro
transcription kit (Ambion). The attenuated V3014 glycoproteins
were used to package all VRP (Bernard et al., 2000). Transcripts
were electroporated into BHK cells. VRP were recovered from
culture supernatants and were purified by ultra-centrifugation
through a 20% sucrose cushion. Concentrated VRP were
resuspended in PBS.
VRP were titered by indirect immunofluorescent staining of
BHK cells. BHK cells were infected with VRP and were fixed
with cold methanol. Cells were permeabilized with Tris
buffered saline–HCl pH 7.6+0.1% Triton X-100+3% bovine
serum albumin (BSA) and blocked with 5% normal horse serum
and 5% BSA. Positive cells were detected with mouse
polyclonal antiserum directed against the VEE nonstructural
proteins, biotinylated horse anti-mouse (Vector Laboratories)
and Texas red-conjugated streptavidin (Molecular Probes).
Each fluorescent cell detected by microscopy was considered
infected by a single infectious unit (IU).Table 1
Oligonucleotide primers used in the construction of the expression plasmids
Primer Sequence (5′ to 3′)
VR21F CAAAGCTGCGCAGC
VR21R#2 CTTGGCGGACTAGAC
VR21F162 CATAGTCTAGTCCGC
R162 TGGCATCGATTATTC
F168 CATAGTCTAGTCCGC
168R AGCCATCGATTAGTT
VR21F199 AGTCTAGTCCGCCAA
R199VR21 CGTAGGCGCGCCTCA
B5R5 TTCAGCTAGCGTCGA
B5R3P TTGTGGTACCTTAGT
162f5pPet40 CTAACCATGGACGGA
162TPpet40 GCATCTCGAGTTCATThymidine kinase negative human osteosarcoma 143B cells
(ATCC) were used to culture the Brighton red strain of cowpox
virus. 143B cells were maintained in MEM (Gibco) supplemen-
ted with L-glutamine, non-essential amino acids and 10% FBS.
Western blots
In order to detect transgene expression from VRP infection,
BHK cells were infected at an MOI of 3 at 37 °C for 1 h. Twelve
hours post-infection, cells were harvested by scraping and were
lysed with RIPA buffer (10 mM Tris–HCl pH 8.0, 140 mM
NaCl, 1% Triton X-100, 0.1% SDS, 1% deoxycholic acid)
supplemented with protease inhibitor cocktail (Sigma). Equal
amounts of proteins were resolved by SDS–PAGE on a 13%
polyacrylamide gel and then transferred to Optitran nitrocellu-
lose membrane. Poxvirus antigens were detected with rabbit
anti-vaccinia virus primary antibody (Biodesign). Horseradish
peroxidase-conjugated α-rabbit (ECL) secondary antibody was
used to detect the primary antibody, and blots were developed
using the Supersignal West Pico Chemiluminescence system
(Pierce).
In order to detect antibody against cowpox virus proteins in
individual mouse sera, 143B cells were infected with cowpox
virus at a multiplicity of infection of 1 pfu/cell. Cells were
harvested at 16 h post-infection and lysed in RIPA buffer.
Proteins in the lysates were resolved by SDS–PAGE in 15% gels
and then transferred to Optitran nitrocellulose membranes.
Mouse sera were diluted 1:200 in 5% milk and were incubated
with membranes overnight at 4 °C prior to development as
above.
Mouse vaccinations and challenges
Five- to six-week-old female BALB/c mice received a
primary inoculation with 1×106 to 4×106 IU VRP in a total
volume of 20 μL diluted in PBS. Ten microliters was inoculated
into each rear footpad. Mice were boosted at the same dose
4 weeks post-prime. Blood was collected in Microtainer serum
separator tubes (Becton Dickinson) by tail vein puncture pre-
prime, immediately pre-boost, and 2 weeks post-boost. Serum
was separated as directed by the manufacturer. Three weeksTTTCC
TATGTCGTAGTCCATTCAGGTTAGCCG
CAAGATGGACGGAACTCTTTTCCCCGGAG
ATATGGTCGCCGTCCAGTC
CAAGATGATGACACCAGAAAACGACGAAGAG
CATTGTTTTAACACAAAAATACTTTCTAACTTCTTGTG
GATGAAAACGATTTCCGTTGTTACGTTGTTATGCG
CGGCAGCAATTTATGGAAC
CGACCATGAAAACGATTTCCGTTGTTACG
GATGATGGTGGTGATGATGATAAGTTGCTTCTAACGATTCTATTTCTTG
ACTCTTTTCCCCGGAGATGAC
ATGGTCGCCGTCCAGTCTGAACATC
450 N.J. Thornburg et al. / Virology 362 (2007) 441–452post-boost, mice were anesthetized with 1.3 mg Ketamine/
0.38 mg xylazine intraperitoneal and challenged with cowpox
virus Brighton red at doses ranging from 1×103 pfu–1×106 pfu
diluted in PBS in a total volume of 5 μL into one nostril.
Mock-challenged mice also were anesthetized, and 5 μL of
PBS was loaded into one nostril. Mice were weighed at the
time of challenge to establish a 100% weight. Weight and
clinical signs of illness were monitored daily for 3 weeks
post-challenge.
Expression and purification of B5, A33 and A27 proteins
B5 protein
Primers B55 and B53P (Table 1) were used to amplify the
ectodomain (amino acids 1 to 278) of the B5 protein of vaccinia
virus WR, with the addition of 5′ NheI and 3′ KpnI restriction
endonuclease sites as well as a His6-tag. The amplified
fragment was cloned into pcDNA3.1+ (Invitrogen). Human
293T cells were transfected with the His-B5 expression
construct, and recombinant B5 protein was purified with a
nickel column from culture supernatant.
A33 protein
The fragment of the gene encoding the ectodomain (amino
acids 81 to 185) of vaccinia virus WR A33 protein was
synthesized de novo (Blue Heron) together with the human
CD5 signal peptide (Aruffo et al., 1990) at the N-terminus and
His6-tag at the C-terminus. The synthetic gene was then cloned
into pcDNA3.1+ (Invitrogen). Human 293T cells were trans-
fected with the His-A33 expression construct, and recombinant
A33 protein was purified with a nickel column from culture
supernatant.
A27 protein
The entire coding region of the A27 gene of cowpox virus
(CPXV162) was PCR amplified using primers 162f5pPet40 and
162TPpet40 and was cloned into plasmid pET-40b(+) (Nova-
gen) NcoI–XhoI (Table 1). The resulting DsbC-A27 fusion
protein contains both N- and C-terminal His tags. Rosetta DE3
E. coli (Novagen) were transformed with pET-40b encoding the
A27 fusion protein, protein expression was induced by
treatment with 1 mM IPTG, and the His-tagged protein was
extracted and purified with Nickel affinity resin, as described by
the manufacturers (Novagen). The A27 protein was dialyzed
against PBS and the purity and size of the protein were
confirmed by SDS–PAGE analysis.
ELISA
Immulon 96 well plates (Fisher) were coated with purified
B5, A33 or A27 (200 ng per well) in carbonate buffer (7.5 mM
Na2CO3/17.4 mM NaHCO3) overnight at 4 °C. Wells were
washed, blocked with 3% BSA/PBS or 10% Blocking Buffer
(Sigma) and incubated with diluted sera. Antibody was detected
with horseradish peroxidase conjugated goat anti-mouse IgG
(Sigma), goat anti-mouse IgG1 (Southern Biotech) or goat anti-
mouse IgG2a (Southern Biotech) and antibody reactivity wasdetected with o-Phenylenediamine dihydrochloride (Sigma) as
directed by the manufacturer. Serum IgG endpoint titers are
reported as the reciprocal of the highest dilution that resulted in
an OD450≥0.2.
Statistical analysis
Statistical analysis utilized the Tukey–Kramer Multiple
Comparisons test using GraphPad InStat 3 software.
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